Key result
Icosapent ethyl added to statins provides cardiovascular benefits by stabilizing and slowing coronary plaque progression.
Why the study?
Despite LDL cholesterol reduction, significant cardiovascular disease risk remains, and EPA may play a crucial role in addressing inflammatory and metabolic pathways contributing to residual risk.
Do omega-3 fatty acids, specifically eicosapentaenoic acid, improve coronary plaque characteristics and reduce cardiovascular risk when added to statins?
Do omega-3 fatty acids, specifically eicosapentaenoic acid, improve coronary plaque characteristics and reduce cardiovascular risk when added to statins?
Answers are grounded in this paper and cite their sources.
Icosapent ethyl (pure EPA) provides cardiovascular benefits and plaque stabilization beyond statin therapy, outperforming other omega-3 fatty acid formulations.
Treatment of established risk factors, especially low-density lipoprotein (LDL) cholesterol, is the cornerstone of preventing atherosclerotic coronary artery disease. Despite reducing LDL cholesterol, there remains a significant risk of cardiovascular disease. Inflammatory and metabolic pathways contribute to recurrence of cardiovascular events, and are often missed in clinical practice. Eicosapentaenoic acid (EPA) may play a crucial role in reducing residual risk of cardiovascular disease. In this review we discuss the clinical applications of omega-3 fatty acids (OM3FAs), their mechanism of action, the difference between pure EPA and docosahexaenoic acid components, and the latest cardiovascular outcome trials and imaging trials evaluating coronary plaque. PubMed and EMBASE were searched to include all the remarkable clinical trials investigating OM3FAs and cardiovascular disease. Beyond statins, additional medications are required to reduce the risk of cardiovascular disease. EPA has shown cardiovascular benefit in addition to statins in large outcome trials. Additionally, multiple serial-imaging studies have demonstrated benefits on plaque progression and stabilization. Due to its pleotropic properties, icosapent ethyl outperforms other OM3FAs in decreasing cardiovascular disease risk in both patients with and without high triglycerides, and is currently recommended as an adjunct to statins. To further strengthen the current evidence, additional research is required to elucidate the inconsistencies between the effects of pure EPA and EPA plus docosahexaenoic acid.
No takes yet. Share an insight, caveat, or question.
Manubolu et al. (2022) conducted a review in Coronary artery disease. Omega-3 fatty acids (Eicosapentaenoic acid) vs. Placebo or statin therapy alone was evaluated. Eicosapentaenoic acid, particularly icosapent ethyl, demonstrates cardiovascular benefits and improves coronary plaque progression and stabilization when used as an adjunct to statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: